Skip to content

Effects of Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Acute Ischemic Stroke

Effects of Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Acute Ischemic Stroke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05843240
Enrollment
128
Registered
2023-05-06
Start date
2023-05-07
Completion date
2024-06-03
Last updated
2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transcranial Magnetic Stimulation

Brief summary

The purpose of this study was to investigate the effect of repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with acute ischemic stroke.

Detailed description

Current studies have shown that repetitive transcranial magnetic stimulation can change the excitability of nerve cells, improve intracerebral artery blood supply, and even reduce the degree of neurological impairment in patients with ischemic stroke. The purpose of this study was to investigate the effect of repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with acute ischemic stroke.

Interventions

PROCEDURERepetitive transcranial magnetic stimulation

After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).

PROCEDURESham repetitive transcranial magnetic stimulation

After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.

Sponsors

Yi Yang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years, both sexes; 2. Clinically definite diagnosis of acute ischemic stroke; 3. Baseline National Institute of Health Stroke Scale (NIHSS) score ≤25; 4. Pre-onset modified Rankin Scale (mRS) score ≤1; 5. Randomized and initiated transcranial magnetic stimulation within 1 week of onset; 6. Subject or legal representative agreed to the treatment and signed the informed consent.

Exclusion criteria

1. Presence of a medical condition such as severe cognitive impairment or mental impairment; 2. Patients with serious physical diseases or who have had craniocerebral surgery; 3. Previous history of epilepsy, family history of epilepsy or presence of seizure provoking factors; 4. Pregnancy or breastfeeding; 5. The presence of metal foreign bodies near the stimulation site, such as intracranial metal implants, cochlear implants, built-in pulse generators (brain pacemakers, cardiac pacemakers), etc.; 6. Patients who are unable to complete cerebral autoregulation, or bilateral temporal window penetration poorly; 7. life expectancy of ≤3 months or inability to complete the study for other reasons; 8. unwillingness to be followed up or poor treatment compliance; 9. Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment, or who have participated in this study; 10. Other conditions that the investigators deemed unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frameDescription
phase difference(PD) in degree0-5 daysA cerebral autoregulation parameter derived from transfer function analysis. Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler. Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size. Transfer function analysis will be used to derive the cerebral autoregulatory parameter.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026